Updates on the use of ctDNA in the management of colorectal cancer
DOI:
https://doi.org/10.18203/2349-2902.isj20260482Keywords:
Circulating tumor DNA, Colorectal cancer, Liquid biopsy, Minimal residual disease, Precision medicineAbstract
Colorectal cancer (CRC) remains a major global health concern as the third most diagnosed cancer and the second leading cause of cancer-related deaths. While early detection through colonoscopy and stool-based screening significantly improves survival, limited adherence and diagnostic sensitivity highlight the need for better non-invasive tools. Circulating tumor DNA (ctDNA), a tumor-specific component of cell-free DNA, has emerged as a promising biomarker that may transform the detection, monitoring, and treatment of CRC. This review compiles and summarizes recent advancements and updates in ctDNA research and evaluates its clinical utility across CRC management. Recent clinical trials, biomarker studies, and comprehensive reviews were examined to evaluate recent advancements in the use of ctDNA in CRC detection and management. ctDNA methylation-based assays have shown high diagnostic accuracy, especially in late-stage CRC, with several multi-gene panels achieving sensitivities and specificities above 90%. Large-scale studies such as DYNAMIC II, GALAXY, and BESPOKE CRC support ctDNA’s role in identifying minimal residual disease (MRD), predicting recurrence, and informing adjuvant treatment decisions. Multiple studies have shown that ctDNA has outperformed carcinoembryonic antigen (CEA) and imaging in CRC surveillance, detecting relapse months in advance. Economic analyses suggest that integrating ctDNA testing into clinical workflows may reduce overall treatment costs by minimizing overtreatment. The results of several major ongoing trials are awaited and are expected to further inform the role of ctDNA in routine CRC care. ctDNA offers a minimally invasive, real-time approach to personalize CRC management across all disease stages. Although challenges remain, particularly in standardization, early-stage detection, and optimal timing of testing, ongoing research continues to support its expanding role in precision oncology.
Metrics
References
Colon Cancer Coalition. Facts, 2025. Available at https://coloncancercoalition.org/coloncancerscreening/facts/. Accessed on 30 July 2025.
Wang Z, He Z, Lin R. Evaluation of a plasma cell-free DNA methylation test for colorectal cancer diagnosis: a multicenter clinical study. BMC Med. 2024;22:436. DOI: https://doi.org/10.1186/s12916-024-03662-y
Hanna M, Dey N, Grady WM. Emerging Tests for Noninvasive Colorectal Cancer Screening. Clin Gastroenterol Hepatol. 2023;21:604-16. DOI: https://doi.org/10.1016/j.cgh.2022.12.008
Tao XY, Li QQ, Zeng Y. Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring. Mol Cancer. 2024;23:145. DOI: https://doi.org/10.1186/s12943-024-02063-2
Stintzing S, Klein-Scory S, Fischer von Weikersthal L. Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study. J Clin Oncol. 2025;43:1463-73. DOI: https://doi.org/10.1200/JCO.24.01174
Malla M, Loree JM, Kasi PM, Parikh AR. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices. J Clin Oncol. 2022;40:2846-57. DOI: https://doi.org/10.1200/JCO.21.02615
El Messaoudi S, Mouliere F, Du Manoir S. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. Clinical Cancer Research. 2016;22:3067-77. DOI: https://doi.org/10.1158/1078-0432.CCR-15-0297
Sánchez-Herrero E, Serna-Blasco R, Robado de Lope L, González-Rumayor V, Romero A, Provencio M. Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis. Front Oncol. 2022;12:943253. DOI: https://doi.org/10.3389/fonc.2022.943253
Gai W, Ji L, Lam WKJ. Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. Clinical Chem. 2018;64:1239-49. DOI: https://doi.org/10.1373/clinchem.2018.290304
O’Leary B, Hrebien S, Beaney M. Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. Clinical Chemistry. 2019;65:1405-13. DOI: https://doi.org/10.1373/clinchem.2019.305805
Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020;17:757-770. DOI: https://doi.org/10.1038/s41571-020-0392-0
Chan HT, Chin YM, Nakamura Y, Low SK. Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications. Cancers (Basel). 2020;12:2277. DOI: https://doi.org/10.3390/cancers12082277
Hajebi Khaniki S, Shokoohi F, Esmaily H, Kerachian MA. Analyzing aberrant DNA methylation in colorectal cancer uncovered intangible heterogeneity of gene effects in the survival time of patients. Sci Rep. 2023;13:22104. DOI: https://doi.org/10.1038/s41598-023-47377-1
Xu F, Yu S, Han J. Detection of Circulating Tumor DNA Methylation in Diagnosis of Colorectal Cancer. Clin Transl Gastroenterol. 2021;12:e00386. DOI: https://doi.org/10.14309/ctg.0000000000000386
Pedersen SK, Symonds EL, Baker RT. Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer. 2015;15:654. DOI: https://doi.org/10.1186/s12885-015-1674-2
Jung G, Hernández-Illán E, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;17:111-30. DOI: https://doi.org/10.1038/s41575-019-0230-y
Chen B, Zhao H, Hu H. Circulating DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer. Sci Rep. 2025;15:13577. DOI: https://doi.org/10.1038/s41598-025-95712-5
Lin WH, Xiao J, Ye ZY. Circulating tumor DNA methylation marker MYO1-G for diagnosis and monitoring of colorectal cancer. Clin Epigenetics. 2021;13:232. DOI: https://doi.org/10.1186/s13148-021-01216-0
Li H, Wang Z, Zhao G. Performance of a MethyLight assay for methylated SFRP2 DNA detection in colorectal cancer tissue and serum. Int J Biol Markers. 2019;34:54-9. DOI: https://doi.org/10.1177/1724600818820536
Potievskaya V, Tyukanova E, Sekacheva M. Prognostic Significance of the Comprehensive Biomarker Analysis in Colorectal Cancer. Life. 2025;15:1100. DOI: https://doi.org/10.3390/life15071100
Chung DC, Gray DM, Singh H. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med. 2024;390:973-983. DOI: https://doi.org/10.1056/NEJMoa2304714
Shaukat A, Burke CA, Chan AT. Clinical Validation of a Circulating Tumor DNA-Based Blood Test to Screen for Colorectal Cancer. JAMA. 2025;334:56-63. DOI: https://doi.org/10.1001/jama.2025.7515
Lockwood CM, Borsu L, Cankovic M. Recommendations for Cell-Free DNA Assay Validations: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2023;25:876-97. DOI: https://doi.org/10.1016/j.jmoldx.2023.09.004
Chen H, An Y, Wang C, Zhou J. Circulating tumor DNA in colorectal cancer: biology, methods and applications. Discover Oncol. 2025;16. DOI: https://doi.org/10.1007/s12672-025-02220-z
Nagayama S, Low SK, Kiyotani K, Nakamura Y. Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. Cancers (Basel). 2021;13:4803. DOI: https://doi.org/10.3390/cancers13194803
Tie J, Cohen JD, Lahouel K. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. New England J Med. 2022;386:2261-72. DOI: https://doi.org/10.1056/NEJMoa2200075
Tie J, Wang Y, Lo SN. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31:1509-18. DOI: https://doi.org/10.1038/s41591-025-03579-w
Kasi PM, Aushev VN, Ensor J, Langer N, Wang CG, Cannon TL, et al. Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study. JCO. 2024;42:9. DOI: https://doi.org/10.1200/JCO.2024.42.3_suppl.9
Nakamura Y, Watanabe J, Akazawa N. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024;30:3272-3283. DOI: https://doi.org/10.1038/s41591-024-03254-6
Taniguchi H, Nakamura Y, Kotani D. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021;112:2915-20. DOI: https://doi.org/10.1111/cas.14926
Bando H, Watanabe J, Kotaka M. A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): The ALTAIR study. JCO. 2025;43:LBA22. DOI: https://doi.org/10.1200/JCO.2025.43.4_suppl.LBA22
Morris VK, Yothers G, Kopetz S. Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study. JCO. 2024;42:5. DOI: https://doi.org/10.1200/JCO.2024.42.3_suppl.5
Tabernero J, Grothey A, Van Cutsem E. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021;39:273-84. DOI: https://doi.org/10.1200/JCO.20.02088
Kopetz S, Murphy DA, Pu J. Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. Nat Med. 2024;30:3261-71. DOI: https://doi.org/10.1038/s41591-024-03235-9
Grancher A, Beaussire L, Manfredi S. Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer. Front Oncol. 2022;12:973167. DOI: https://doi.org/10.3389/fonc.2022.973167
Chidharla A, Rapoport E, Agarwal K. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2023;24:10230. DOI: https://doi.org/10.3390/ijms241210230
Negro S, Pulvirenti A, Trento C. Circulating Tumor DNA as a Real-Time Biomarker for Minimal Residual Disease and Recurrence Prediction in Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2025;26:2486. DOI: https://doi.org/10.3390/ijms26062486
Fan X, Zhang J, Lu D. CtDNA’s prognostic value in patients with early-stage colorectal cancer after surgery: A meta-analysis and systematic review. Medicine (Baltimore). 2023;102:e32939. DOI: https://doi.org/10.1097/MD.0000000000032939
Faulkner LG, Howells LM, Pepper C, Shaw JA, Thomas AL. The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis. Br J Cancer. 2023;128:297-309. DOI: https://doi.org/10.1038/s41416-022-02017-9
Tie J, Wang Y, Cohen J. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. PLoS Med. 2021;18:e1003620. DOI: https://doi.org/10.1371/journal.pmed.1003620
Henriksen TV, Tarazona N, Frydendahl A. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. Clin Cancer Res. 2022;28:507-17. DOI: https://doi.org/10.1158/1078-0432.CCR-21-2404
Ma Y, Li Y, Wen Z. Genome wide identification of novel DNA methylation driven prognostic markers in colorectal cancer. Sci Rep. 2024;14:15654. DOI: https://doi.org/10.1038/s41598-024-60351-9
Pedersen SK, Symonds EL, Roy AC, Cornthwaite KJ, LaPointe LC, Young GP. Detection of methylated BCAT1 and IKZF1 after curative-intent treatment as a prognostic indicator for colorectal cancer recurrence. Cancer Med. 2023;12:1319-29. DOI: https://doi.org/10.1002/cam4.5008
Krell M, Llera B, Brown ZJ. Circulating Tumor DNA and Management of Colorectal Cancer. Cancers (Basel). 2023;16:21. DOI: https://doi.org/10.3390/cancers16010021
Bahadoer RR, Dijkstra EA, van Etten B. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29-42. DOI: https://doi.org/10.1016/S1470-2045(20)30555-6
Zou D, Day R, Cocadiz JA. Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer. Carcinogenesis. 2020;41:1507-17. DOI: https://doi.org/10.1093/carcin/bgaa102
Dawood ZS, Alaimo L, Lima HA. Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen: Comparison of Surveillance Strategies Among Patients Who Underwent Resection of Colorectal Cancer-A Systematic Review and Meta-analysis. Ann Surg Oncol. 2023;30:259-74. DOI: https://doi.org/10.1245/s10434-022-12641-7
Symonds EL, Pedersen SK, Murray D. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. Cancer. 2020;126:1460-9. DOI: https://doi.org/10.1002/cncr.32695
Chen G, Peng J, Xiao Q. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. J Hemat Oncol. 2021;14:80. DOI: https://doi.org/10.1186/s13045-021-01089-z
Coffey K. Liquid Biopsy Detects Colorectal Cancer Recurrence Months Early: AACR 2025. European Medical J. 2025.
Slater S, Bryant A, Aresu M. Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study. Clin Cancer Res. 2024;30:3459-69. DOI: https://doi.org/10.1158/1078-0432.CCR-24-0226
Ke-Feng D. A Randomized Controlled Trial of CAPEOX vs Observation in Early-Stage Colorectal Cancer Patients With Positive MRD After Curative Surgery. clinicaltrials.gov, 2023. Available at: https://clinicaltrials.gov/study/NCT0569. Accessed on 30 July 2025.
Exact Sciences Corporation. CORRECT-MRD II: Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease. clinicaltrials.gov, 2025. Available at: https://clinicaltrials.gov/study/NCT0283. Accessed on 30 July 2025.
Solar Vasconcelos JP, Titmuss E, Navarro F. Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay. JCO. 2024;42:e15625. DOI: https://doi.org/10.1200/JCO.2024.42.16_suppl.e15625
Natera Inc. BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer. clinicaltrials.gov, 2023. Available at: https://clinicaltrials.gov/ study/NCT04264. Accessed on 30 July 2025.
Australian New Zealand Clinical Trials Registry. ANZCTR - Registration, 2025. Available at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373948. Accessed 30 July 2025.
NRG Oncology. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease. clinicaltrials.gov, 2025. Available at: https://clinicaltrials.gov/study/NCT0517. Accessed on 30 July 2025.
Li Y, Heer AK, Sloane HS. Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans. JAMA Health Forum. 2024;5:e241270. DOI: https://doi.org/10.1001/jamahealthforum.2024.1270
Guigal-Stephan N, Lockhart B, Moser T, Heitzer E. A perspective review on the systematic implementation of ctDNA in phase I clinical trial drug development. J Exp Clin Cancer Res. 2025;44:79. DOI: https://doi.org/10.1186/s13046-025-03328-4
Downloads
Published
How to Cite
Issue
Section
